Blog
The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch
Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries [...]
